Cargando…

The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study

An efficient asymmetric synthesis of GlaxoSmithKline’s potent PDE4 inhibitor was accomplished in eight steps from a catechol-derived nitroalkene. The key intermediate (3-acyloxymethyl-substituted 1,2-oxazine) was prepared in a straightforward manner by tandem acylation/(3,3)-sigmatropic rearrangemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Pospelov, Evgeny V., Golovanov, Ivan S., Ioffe, Sema L., Sukhorukov, Alexey Yu.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464803/
https://www.ncbi.nlm.nih.gov/pubmed/32784502
http://dx.doi.org/10.3390/molecules25163613
_version_ 1783577447386578944
author Pospelov, Evgeny V.
Golovanov, Ivan S.
Ioffe, Sema L.
Sukhorukov, Alexey Yu.
author_facet Pospelov, Evgeny V.
Golovanov, Ivan S.
Ioffe, Sema L.
Sukhorukov, Alexey Yu.
author_sort Pospelov, Evgeny V.
collection PubMed
description An efficient asymmetric synthesis of GlaxoSmithKline’s potent PDE4 inhibitor was accomplished in eight steps from a catechol-derived nitroalkene. The key intermediate (3-acyloxymethyl-substituted 1,2-oxazine) was prepared in a straightforward manner by tandem acylation/(3,3)-sigmatropic rearrangement of the corresponding 1,2-oxazine-N-oxide. The latter was assembled by a (4 + 2)-cycloaddition between the suitably substituted nitroalkene and vinyl ether. Facile acetal epimerization at the C-6 position in 1,2-oxazine ring was observed in the course of reduction with NaBH(3)CN in AcOH. Density functional theory (DFT) calculations suggest that the epimerization may proceed through an unusual tricyclic oxazolo(1,2)oxazinium cation formed via double anchimeric assistance from a distant acyloxy group and the nitrogen atom of the 1,2-oxazine ring.
format Online
Article
Text
id pubmed-7464803
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74648032020-09-04 The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study Pospelov, Evgeny V. Golovanov, Ivan S. Ioffe, Sema L. Sukhorukov, Alexey Yu. Molecules Article An efficient asymmetric synthesis of GlaxoSmithKline’s potent PDE4 inhibitor was accomplished in eight steps from a catechol-derived nitroalkene. The key intermediate (3-acyloxymethyl-substituted 1,2-oxazine) was prepared in a straightforward manner by tandem acylation/(3,3)-sigmatropic rearrangement of the corresponding 1,2-oxazine-N-oxide. The latter was assembled by a (4 + 2)-cycloaddition between the suitably substituted nitroalkene and vinyl ether. Facile acetal epimerization at the C-6 position in 1,2-oxazine ring was observed in the course of reduction with NaBH(3)CN in AcOH. Density functional theory (DFT) calculations suggest that the epimerization may proceed through an unusual tricyclic oxazolo(1,2)oxazinium cation formed via double anchimeric assistance from a distant acyloxy group and the nitrogen atom of the 1,2-oxazine ring. MDPI 2020-08-08 /pmc/articles/PMC7464803/ /pubmed/32784502 http://dx.doi.org/10.3390/molecules25163613 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pospelov, Evgeny V.
Golovanov, Ivan S.
Ioffe, Sema L.
Sukhorukov, Alexey Yu.
The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study
title The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study
title_full The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study
title_fullStr The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study
title_full_unstemmed The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study
title_short The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study
title_sort cyclic nitronate route to pharmaceutical molecules: synthesis of gsk’s potent pde4 inhibitor as a case study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464803/
https://www.ncbi.nlm.nih.gov/pubmed/32784502
http://dx.doi.org/10.3390/molecules25163613
work_keys_str_mv AT pospelovevgenyv thecyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy
AT golovanovivans thecyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy
AT ioffesemal thecyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy
AT sukhorukovalexeyyu thecyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy
AT pospelovevgenyv cyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy
AT golovanovivans cyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy
AT ioffesemal cyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy
AT sukhorukovalexeyyu cyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy